Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Adjuvant Therapy in Locally Advanced HNSCC
NCT03678649Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03678649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678649.